Managers / Q3 2019 · view latest →
Versant Venture Management, LLC
CIK 0001560009 · ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO, CA, 94104 · 650-233-7877
Summary
Versant Venture Management, LLC reported $258.5B in U.S.-listed holdings across 8 positions for Q3 2019.
The portfolio is heavily concentrated: Crispr Therapeutics alone accounts for 67.1% of reported value.
Compared with Q2 2019, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 68.6% · $177.3B
- Common Stock · 31.4% · $81.2B
Quarter-over-Quarter Changes full breakdown →
vs Q2 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| OpGen, Inc. | SOLD OUT | −102.2K | 0 | −$40M | $0 |
| VCYTVeracyte, Inc. | TRIMMED | −1.21M | 1.21M | −$39.8B | $28.9B |
| CRISPR Therapeutics AG | HELD | −15.0K | 4.23M | −$26.6B | $173.5B |
| 2JQGritstone Oncology, Inc. | HELD | +0 | 3.10M | −$7.8B | $26.8B |
| BOLDEURAudentes Therapeutics, Inc. | HELD | +0 | 553.9K | −$5.4B | $15.6B |
| OCULOcular Therapeutix, Inc. | HELD | +0 | 2.22M | −$3.0B | $6.7B |
| CLVSEURClovis Oncology, Inc. | HELD | +0 | 101.9K | −$1.1B | $400M |
| CymaBay Therapeutics, Inc. | HELD | +0 | 543.8K | −$1.1B | $2.8B |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CRISPR Therapeutics AG | Common Stock | 67.15% | $173.5B | 4.23M |
| 2 | VCYTVeracyte, Inc.history → | Common Stock | 11.19% | $28.9B | 1.21M |
| 3 | 2JQGritstone Oncology, Inc.history → | Common Stock | 10.37% | $26.8B | 3.10M |
| 4 | BOLDEURAudentes Therapeutics, Inc.history → | Common Stock | 6.02% | $15.6B | 553.9K |
| 5 | OCULOcular Therapeutix, Inc.history → | Common Stock | 2.61% | $6.7B | 2.22M |
| 6 | Second Sight Medical Products, Inc. | Common Stock | 1.43% | $3.7B | 4.49M |
| 7 | CymaBay Therapeutics, Inc. | Common Stock | 1.08% | $2.8B | 543.8K |
| 8 | CLVSEURClovis Oncology, Inc.history → | Common Stock | 0.15% | $400M | 101.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $141M | 8 | May 5, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $151M | 7 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $212M | 9 | Nov 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $82M | 8 | Aug 11, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $60M | 7 | May 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $87M | 7 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $64M | 6 | Nov 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $77M | 8 | Aug 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $103M | 7 | May 3, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $389M | 7 | Feb 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $188M | 8 | Nov 3, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $84M | 8 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $48M | 7 | May 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $48M | 7 | Feb 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $59M | 8 | Nov 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $65M | 8 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $100M | 10 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $187M | 10 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $242M | 11 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $302M | 11 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $513M | 11 | May 7, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $963M | 12 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | Under review | 11 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $696.1B | 12 | Jul 20, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $364.6B | 9 | Apr 28, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $331.8B | 7 | Jan 21, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $258.5B | 8 | Oct 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $343.2B | 9 | Jul 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $303.6B | 9 | Apr 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $202.0B | 10 | Jan 22, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.